Technology

OWN TECHNOLOGY DEVELOPMENT

Lentisoma

VIVEbiotech´s technology development strategy is focused on providing a response to the main hurdles that currently exist within the gene therapy field:

  • The need for cost-effective processes.
  • The enhancement of the safety profile of viral vectors.

For this reason, VIVEbiotech is working in the following areas:

  • The development of improved producer cell lines and manufacturing processes.
  • New pseudotyping strategies.
  • Lentisoma: a worldwide patented technology (WO 2015/078999 A1) consisting of an episomal non-integrative stable lentiviral vector that provides a lasting, stable, consistent expression of the transgene in dividing and non-dividing cells.

Contact us

Mikeletegi Pasealekua 81, San Sebastián 20009, Gipuzkoa (SPAIN)

JOIN US

linkedinb